CFE Backs Action Against Germany’s Drug Price Controls
Aug 11
1 min read
The Center for a Free Economy (CFE) submitted comments supporting U.S. Trade Representative Jamieson Greer’s Section 301 investigation into Germany’s pricing of innovative pharmaceutical products. CFE argues that Germany’s price controls undervalue new medicines, discourage research and development, and shift more of the cost of pharmaceutical innovation onto American patients.
CFE urged USTR to press Germany to end these market-distorting policies and encouraged the administration to challenge similar practices in other countries that free-ride on American pharmaceutical innovation.
Read CFE’s full comments below:
https://casinoenlignesansverif.com caught my attention because the free-rider argument in the CFE comments is the part I keep coming back to, since American patients effectively subsidizing R&D for other countries feels like a trade issue that never gets framed that way in public debate. If Germany's controls keep pushing costs onto the U.S. market, it's hard to see how innovation incentives survive long term. I work adjacent to pharma pricing, and the gap between what politicians say about "fair pricing" and how that actually plays out across borders is wider than most people realize.